Study #2022-0698
A phase 1-2, open-label study of the safety, pharmacokinetics, pharmacodynamics, and preliminary activity of Tolinapant in combination with Oral Decitabine/Cedazuridine and oral Decitabine/Cedazuridine alone in subjects with relapsed/refractory peripheral t-cell lymphoma.
MD Anderson Study Status
Not Accepting
Treatment Agent
Tolinapant, Decitabine + Cedazuridine
Description
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed/Refractory Peripheral T-cell Lymphoma
Study phase:
Physician name:
Luis Malpica Castillo
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-833-767-1887
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.